To report the results of OCARINA II (NCT05232825), a Phase III, randomized, open-label, controlled study designed to demonstrate non-inferiority in serum exposure of ocrelizumab (OCR) when administered via subcutaneous (SC) versus intravenous (IV) routes.
No takes yet. Share an insight, caveat, or question.
Newsome et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: